FDA Advisory Committee Votes Unanimously in Favor Of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-risk PopulationsBusiness Wire • 09/17/21
Influential FDA Panel Votes Down Widespread Pfizer Booster; Approves Third Shot For 65 & Older + Those At “High Risk”Deadline • 09/17/21
FDA Panel Votes Against Approval Of Pfizer/BioNTech's COVID-19 Booster Shot For General PublicBenzinga • 09/17/21
FDA Advisory Panel Recommends Against Pfizer Covid Boosters—Except For People Over 65Forbes • 09/17/21
Why COVID Vaccine Stocks BioNTech, Moderna, and Novavax Are Sliding While Ocugen Is RisingThe Motley Fool • 09/17/21
Pfizer submits data to FDA showing side effects from Covid booster shots are similar to the second doseCNBC • 09/15/21